These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27552545)

  • 1. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Donze SH; Festen DA; van Alfen-van der Velden JA; Stijnen T; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4110-4116. PubMed ID: 27552545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.
    Kuppens RJ; Bakker NE; Siemensma EP; Donze SH; Stijnen T; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):297-304. PubMed ID: 27689944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.
    Gondoni LA; Vismara L; Marzullo P; Vettor R; Liuzzi A; Grugni G
    J Endocrinol Invest; 2008 Sep; 31(9):765-72. PubMed ID: 18997487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.
    Kuppens RJ; Mahabier EF; Bakker NE; Siemensma EP; Donze SH; Hokken-Koelega AC
    Orphanet J Rare Dis; 2016 Nov; 11(1):153. PubMed ID: 27852283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.
    Gravholt CH; Naeraa RW; Brixen K; Kastrup KW; Mosekilde L; Jørgensen JO; Christiansen JS
    Pediatrics; 2002 Nov; 110(5):889-96. PubMed ID: 12415026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C; Hilding A; Jacobsson H; Thorén M
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4943-50. PubMed ID: 20702523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
    Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Frystyk J; Christiansen JS; Höybye C
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome.
    Marzullo P; Marcassa C; Minocci A; Campini R; Eleuteri E; Gondoni LA; Aimaretti G; Sartorio A; Scacchi M; Grugni G
    J Clin Endocrinol Metab; 2015 May; 100(5):2106-14. PubMed ID: 25710568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.
    Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
    Endocr J; 2018 Nov; 65(11):1127-1137. PubMed ID: 30185718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.